Milestone Pharmaceuticals Inc. Common Shares (MIST) Stock Price

MISTStock

$1.16−35.91%52W

Market Cap$144.42M

P/E—

PEG Ratio—

Div yield—

Beta0.99

MIST Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-45.26%

Price vs S&P 500 (4W)2.03%

VGM Score33.10

Book Value / Share (Quarterly)$0.31

P/TBV (Annual)1.39x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-32.38%

Cash Flow / Share (Quarterly)$-0.44

Price vs S&P 500 (YTD)-55.40%

Net Profit Margin (TTM)-2436.94%

EPS (TTM)$-0.68

10-Day Avg Trading Volume1.59M

EPS Excl Extra (TTM)$-0.68

EPS (Annual)$-0.75

ROI (Annual)-63.72%

Net Profit Margin (5Y Avg)-1148.11%

Cash / Share (Quarterly)$1.56

ROA (Last FY)-55.53%

EBITD / Share (TTM)$-0.65

ROE (5Y Avg)-189.76%

Operating Margin (TTM)-2293.72%

Cash Flow / Share (Annual)$-0.46

P/B Ratio3.68x

P/B Ratio (Quarterly)3.88x

Net Income / Employee (Annual)$-1,659,400

EV / Revenue (TTM)110.75x

Net Interest Coverage (TTM)-67.69x

ROA (TTM)-61.80%

EPS Incl Extra (Annual)$-0.75

Current Ratio (Annual)8.01x

Quick Ratio (Quarterly)9.03x

3-Month Avg Trading Volume1.41M

52-Week Price Return-35.91%

Revenue / Employee (TTM)$46,900

Tangible BV / Share (Quarterly)$0.85

P/S Ratio (Annual)85.76x

Asset Turnover (Annual)0.01x

52-Week High$3.06

Operating Margin (5Y Avg)-1175.64%

EPS Excl Extra (Annual)$-0.75

CapEx CAGR (5Y)-39.58%

Tangible BV CAGR (5Y)20.62%

26-Week Price Return-33.33%

Quick Ratio (Annual)7.83x

13-Week Price Return-19.44%

Total Debt / Equity (Annual)1.37x

Current Ratio (Quarterly)9.18x

Enterprise Value$197.58M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-39.38%

Revenue / Employee (Annual)$40,700

Pretax Margin (Annual)-4078.78%

Cash / Share (Annual)$1.00

3-Month Return Std Dev59.54%

Net Income / Employee (TTM)$-1,799,000

ROE (Last FY)-150.97%

Net Interest Coverage (Annual)-21.17x

EPS Basic Excl Extra (Annual)$-0.75

Receivables Turnover (TTM)3.31x

Total Debt / Equity (Quarterly)3.78x

EPS Incl Extra (TTM)$-0.68

Receivables Turnover (Annual)5.90x

ROI (TTM)-47.75%

P/S Ratio (TTM)74.32x

Pretax Margin (5Y Avg)-1148.11%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$1.94

Price vs S&P 500 (52W)-54.47%

Year-to-Date Return-42.57%

5-Day Price Return11.54%

EPS Normalized (Annual)$-0.75

ROA (5Y Avg)-60.80%

Net Profit Margin (Annual)-4078.78%

Month-to-Date Return4.50%

Cash Flow / Share (TTM)$-1.38

EBITD / Share (Annual)$-0.74

Operating Margin (Annual)-4019.40%

LT Debt / Equity (Annual)1.37x

ROI (5Y Avg)-68.40%

LT Debt / Equity (Quarterly)3.78x

EPS Basic Excl Extra (TTM)$-0.68

P/TBV (Quarterly)3.24x

P/B Ratio (Annual)4.12x

Pretax Margin (TTM)-2436.94%

Book Value / Share (Annual)$0.39

Price vs S&P 500 (13W)-21.40%

Beta0.99x

Revenue / Share (TTM)$0.01

ROE (TTM)-169.03%

52-Week Low$1.00

vGradeD

mGradeD

vgmGradeD

MIST Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.19	-$0.21	-9.09%(-$0.02)
Q1 2026	May 13, 2026	$0.19	-$0.20	-206.67%(-$0.39)
Q4 2025	Mar 20, 2026	-$0.18	-$0.15	+15.10%(+$0.03)
Q3 2025	Nov 12, 2025	-$0.16	-$0.12	+26.83%(+$0.04)
Q2 2025	Aug 12, 2025	-$0.18	-$0.20	-11.11%(-$0.02)

MIST Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.08

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
MISTMilestone Pharmaceuticals Inc. Common Shares	D	—	D	$1.16
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Milestone Pharmaceuticals Inc. Common Shares

Milestone Pharmaceuticals is a biopharmaceutical company developing etripamil, a rapid-onset calcium channel blocker delivered as a nasal spray for cardiovascular conditions. The company is commercializing etripamil for paroxysmal supraventricular tachycardia (PSVT) treatment and has a Phase 2 clinical trial underway for atrial fibrillation with rapid ventricular rate (AFib-RVR).